Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy.
Yuko Nitahara-KasaharaSoya NakayamaKoichi KimuraSho YamaguchiYuko KakiuchiChikako NitoMasahiro HayashiTomoyuki NakaishiYasuyoshi UedaTakashi OkadaPublished in: Stem cell research & therapy (2023)
Early systemic hAMSC administration in mdx mice ameliorated progressive phenotypes, including pathological inflammation and motor dysfunction, resulting in the long-term improvement of skeletal and cardiac muscle function. The therapeutic effects might be associated with the immunosuppressive properties of hAMSCs via M2 macrophage polarization. This treatment strategy could provide therapeutic benefits to DMD patients.
Keyphrases
- duchenne muscular dystrophy
- mouse model
- end stage renal disease
- skeletal muscle
- oxidative stress
- ejection fraction
- muscular dystrophy
- newly diagnosed
- multiple sclerosis
- prognostic factors
- bone marrow
- peritoneal dialysis
- left ventricular
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- combination therapy